Andrew M. Evens, DO, on Gray Zone Lymphoma: Results From a Multicenter Study

2017 ASH Annual Meeting
Tweet this page

Andrew M. Evens, DO, of Tufts University, discusses findings on the effectiveness of DLBCL-based therapy for patients whose disease fell between diffuse large B-cell and classical Hodgkin lymphoma (Abstract 375).

Advertisement

Advertisement



Advertisement